Search

Amgen Inc

Cerrado

SectorSanidad

409.97 4.27

Resumen

Variación precio

24h

Actual

Mínimo

379.52

Máximo

394.43

Métricas clave

By Trading Economics

Ingresos

-3.6B

-1.8B

Ventas

1.4B

10B

P/B

Media del Sector

23.681

56.432

BPA

6.29

Rentabilidad por dividendo

2.6

Margen de beneficios

-18.092

Empleados

31,500

EBITDA

-416M

3.4B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+3.39% upside

Dividendos

By Acuity

Rentabilidad por dividendo

Media del Sector

2.60%

2.27%

Próximas Ganancias

3 nov 2026

Fecha Próximo Dividendo

11 dic 2026

Próxima Fecha de Ex Dividendo

20 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

1.8B

206B

Apertura anterior

405.7

Cierre anterior

409.97

Noticias sobre sentimiento de mercado

By Acuity

53%

47%

247 / 339 Clasificación en Healthcare

Amgen Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

18 sept 2026, 20:06 UTC

Amgen Inc is trading higher on Friday, having advanced since Thursday's close, despite pulling back from an earlier session peak.

17 sept 2026, 19:46 UTC

Macro Event

Amgen Inc is trading modestly higher, despite earlier fluctuations and remaining below its 20-day moving average amid a decline in U.S. jobless claims.

16 sept 2026, 20:10 UTC

News

Amgen Inc has expanded its partnership with Veeva Systems, selecting Veeva Vault CRM to enhance global commercial execution, as shares trade slightly higher.

15 sept 2026, 23:01 UTC

Amgen Inc shares are higher in after-market trading, reflecting a recovery from earlier losses despite being below its 20-day moving average and one-month range.

14 sept 2026, 20:08 UTC

Social Media
News

Amgen Inc. shares rise after FDA approval for IMDELLTRA, reducing monitoring time for patients with extensive-stage small cell lung cancer. Positive sentiment noted on social media.

11 sept 2026, 20:08 UTC

Macro Event

Amgen Inc shares are lower today following a drop in the Michigan Consumer Sentiment index, raising concerns over inflation and household budgets.

10 sept 2026, 23:41 UTC

Amgen Inc. shares are higher in after-market trading, continuing a modest advance since Thursday's close, despite four consecutive lower daily closes.

8 sept 2026, 20:03 UTC

News
Correlated Moves

Amgen Inc shares are lower today following Novartis' trial failure and a downgrade by BMO Capital to Market Perform, amid significant sell-off pressure.

4 sept 2026, 23:02 UTC

Amgen Inc shares are lower in after-market hours, reflecting ongoing weakness. The stock is trading below its 20-day moving average and near a one-month low.

3 sept 2026, 20:08 UTC

News

Erste Group Bank raised Amgen's FY2027 EPS estimate to $24.43, surpassing consensus. Shares are higher, continuing a trend of gains this week.

2 sept 2026, 23:01 UTC

News

Amgen Inc. shares are lower in after-market hours despite announcing participation in the 2026 Wells Fargo Healthcare Conference on September 10, 2026.

1 sept 2026, 23:06 UTC

Amgen Inc shares are higher in after-market trading, reflecting a notable rise since Tuesday's close and positioning the stock above its 20-day moving average.

31 ago 2026, 23:01 UTC

Amgen Inc's shares are higher in after-market trading, rebounding from an earlier dip and reaching a notable high since Monday's close.

28 ago 2026, 23:56 UTC

Amgen Inc shares are lower in after-market hours, continuing a trend of declines after four consecutive sessions of lower finishes. No specific news was identified.

27 ago 2026, 23:02 UTC

Event

Amgen Inc. shares are higher in after-market trading following positive Phase 3 CROSSING trial results for TEZSPIRE in eosinophilic esophagitis patients.

26 ago 2026, 23:51 UTC

Amgen Inc shares are lower in after-market hours following a volatile session. Broader inflation concerns were highlighted by the Commerce Department's latest price index.

25 ago 2026, 23:16 UTC

Amgen Inc. shares were higher in after-market hours, supported by a decline in crude oil prices and decreasing treasury yields, indicating overall strength.

24 ago 2026, 23:51 UTC

Amgen Inc. shares are lower in after-market trading with no specific news identified. The stock remains above its 20-day moving average.

21 ago 2026, 20:06 UTC

Event

Amgen Inc. went ex-dividend today, distributing $2.52 per share, as shares trade higher since Thursday's close amid a strong broader market.

20 ago 2026, 23:21 UTC

Amgen Inc. shares are lower in after-market trading, with no specific news identified. Rising U.S. Treasury yields contribute to broader market pressure.

19 ago 2026, 22:56 UTC

Amgen Inc. shares declined slightly in after-hours trading, reflecting a minor decrease since Wednesday's close. The stock remains well above its 20-day moving average.

18 ago 2026, 23:26 UTC

Amgen Inc shares are higher during after-market hours, maintaining a strong position above its 20-day moving average despite broader market pressures.

17 ago 2026, 22:01 UTC

Amgen Inc shares are trading lower in after-market hours. Broader market volatility, influenced by rising crude oil prices, may be affecting investor sentiment.

14 ago 2026, 19:46 UTC

News

Amgen shares are lower today despite Barclays raising the price target to $380, influenced by a decline in U.S. retail sales for July.

13 ago 2026, 20:06 UTC

News

Amgen Inc reported second-quarter revenue of $10.05 billion, exceeding expectations. The company raised its full-year revenue and EPS guidance, contributing to shares moving higher.

12 ago 2026, 19:56 UTC

News

Amgen Inc plans to open a new Science and Innovation Center in Hyderabad by 2027, enhancing its global R&D network. Shares are gaining today.

11 ago 2026, 19:41 UTC

Social Media
News

Amgen Inc shares declined during Tuesday's session after peaking earlier. The stock remains above its 20-day moving average amid social media discussions on its long-term trajectory.

7 ago 2026, 19:22 UTC

News

Amgen Inc shares are higher, supported by strong Q2 results and positive guidance revisions. The Biotechnology sub-sector is also advancing today.

6 ago 2026, 19:56 UTC

Social Media
News

Amgen shares are lower today despite a price target increase from Bernstein. The stock reached a session high before retracing to midday lows.

5 ago 2026, 19:52 UTC

Social Media
News

Amgen Inc. shares advanced following strong Q2 earnings and raised revenue guidance. Analysts from TD Cowen and Scotiabank maintained "Buy" ratings with high price targets.

Comparación entre iguales

Cambio de precio

Amgen Inc previsión

Precio Objetivo

By TipRanks

3.39% repunte

Estimación a 12 Meses

Media 398.727 USD  3.39%

Máximo 460 USD

Mínimo 230 USD

De acuerdo con 24 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Amgen Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

24 ratings

9

Comprar

13

Mantener

2

Vender

Sentimiento

By Acuity

247 / 339 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.